Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2016-05-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/446209 |
| _version_ | 1818425897167880192 |
|---|---|
| author | Corey A. Carter Bryan Oronsky Scott Caroen Jan Scicinski Aiste Degesys Pedro Cabrales Tony R. Reid Christina Brzezniak |
| author_facet | Corey A. Carter Bryan Oronsky Scott Caroen Jan Scicinski Aiste Degesys Pedro Cabrales Tony R. Reid Christina Brzezniak |
| author_sort | Corey A. Carter |
| collection | DOAJ |
| description | Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) involving pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a partial response after only 4 cycles. The patient had received a platinum drug twice before, in 2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for SCLC, suggesting that RRx-001 pretreatment may sensitize or resensitize refractory SCLC patients to first-line chemotherapy. |
| first_indexed | 2024-12-14T14:21:14Z |
| format | Article |
| id | doaj.art-c53dfe35928f46b0a955e22b98939a7c |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-14T14:21:14Z |
| publishDate | 2016-05-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-c53dfe35928f46b0a955e22b98939a7c2022-12-21T22:58:04ZengKarger PublishersCase Reports in Oncology1662-65752016-05-019228528910.1159/000446209446209Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum DoubletsCorey A. CarterBryan OronskyScott CaroenJan ScicinskiAiste DegesysPedro CabralesTony R. ReidChristina BrzezniakSmall-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) involving pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a partial response after only 4 cycles. The patient had received a platinum drug twice before, in 2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for SCLC, suggesting that RRx-001 pretreatment may sensitize or resensitize refractory SCLC patients to first-line chemotherapy.http://www.karger.com/Article/FullText/446209Partial responseRRx-001Refractory small-cell lung cancerPlatinum doublets |
| spellingShingle | Corey A. Carter Bryan Oronsky Scott Caroen Jan Scicinski Aiste Degesys Pedro Cabrales Tony R. Reid Christina Brzezniak Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets Case Reports in Oncology Partial response RRx-001 Refractory small-cell lung cancer Platinum doublets |
| title | Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_full | Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_fullStr | Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_full_unstemmed | Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_short | Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_sort | partial response in an rrx 001 primed patient with refractory small cell lung cancer after a third introduction of platinum doublets |
| topic | Partial response RRx-001 Refractory small-cell lung cancer Platinum doublets |
| url | http://www.karger.com/Article/FullText/446209 |
| work_keys_str_mv | AT coreyacarter partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT bryanoronsky partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT scottcaroen partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT janscicinski partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT aistedegesys partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT pedrocabrales partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT tonyrreid partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT christinabrzezniak partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets |